SCHEMBL6535883

SCHEMBL6535883

[CH2]C1CCN(S(=O)(=O)CCc2ccc(F)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GPR183 P32249 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MMP13 P45452 2/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
POLB P06746 1/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HTR7 P34969 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5347221 0.83 LMNA (0.46) LMNASMN1; SMN2GPR183L3MBTL1HTR2A
SCHEMBL5798436 0.75 HRH1 (0.51) LMNASMN1; SMN2GPR183L3MBTL1
SCHEMBL5355745 0.74 GRIN2B (0.57) LMNASMN1; SMN2GPR183
SCHEMBL5366612 0.72 HDAC6 (0.52) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5352632 0.71 LMNA (0.48) LMNASMN1; SMN2GPR183ALDH1A1MEN1
SCHEMBL30728596 0.70 LMNA (0.63) LMNASMN1; SMN2GPR183ALDH1A1MAPT
SCHEMBL5411893 0.69 BCHE (0.55)
SCHEMBL5365327 0.69 KMT2A (0.51) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5352124 0.68 LMNA (0.60) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2441516 0.67 TAAR1 (0.50) MMP13HTR2AHTR2CMMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399160-A4 NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES MERCK & CO INC (US) 2004-08-25 EP disclosed
EP-1399160-A2 NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES Merck & Co., Inc. (US) 2004-03-24 EP disclosed
WO-2002100352-A2 NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES MERCK & CO., INC. (US) 2002-12-19 WO disclosed